CAS 1005402-19-6

Fórmula: C18H23N3O2

InChI: InChI=1S/C18H23N3O2/c1-14-4-2-11-21(14)12-3-13-23-16-7-5-15(6-8-16)17-9-10-18(22)20-19-17/h5-10,14H,2-4,11-13H2,1H3,(H,20,22)/t14-/m1/s1

Clave InChI: XUKROCVZGZNGSI-CQSZACIVSA-N

SMILES: C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3

6-[4-[3-[(2R)-2-Methyl-1-pyrrolidinyl]propoxy]phenyl]-3(2H)-pyridazinone

CAS: 1005402-19-6

Fórmula: C₁₈H₂₃N₃O₂

Pureza: 98%

Forma y color: Solid

Peso molecular: 313.3941

Ref: IN-DA023P1F

Irdabisant

CAS: 1005402-19-6

Irdabisant

Fórmula: C₁₈H₂₃N₃O₂

Pureza: ≥98%

Peso molecular: 313.39

Ref: 54-BUP12407

Irdabisant

CAS: 1005402-19-6

Irdabisant (CEP-26401) is an H3R antagonist/inverse agonist, BBB permeable, with cognition-enhancing effects for schizophrenia/cognitive research.

Fórmula: C₁₈H₂₃N₃O₂

Pureza: 99.96%

Forma y color: White Solid

Peso molecular: 313.39

Ref: TM-T32191

Irdabisant

CAS: 1005402-19-6

Irdabisant is a novel small-molecule therapeutic, which functions as a histamine H3 receptor antagonist or inverse agonist. This compound is chemically synthesized and designed to target the central nervous system. The mode of action involves the selective inhibition of presynaptic H3 receptors, which are primarily responsible for modulating the release of histamine and other neurotransmitters such as acetylcholine, norepinephrine, and dopamine. By inhibiting these receptors, Irdabisant enhances neurotransmitter release, facilitating improved synaptic transmission.

Fórmula: C₁₈H₂₃N₃O₂

Pureza: Min. 95%

Peso molecular: 313.39 g/mol

Ref: 3D-BI184163